Pharmaceutical Executive Joins Mesoblast as Chief Financial Officer
News Aug 26, 2014
Mesoblast Limited has announced the appointment of pharmaceutical executive Mr Paul Hodgkinson as Mesoblast Chief Financial Officer.
Mr Hodgkinson has broad and high-level international pharmaceutical experience in all aspects of finance, strategic planning, business development and licensing, manufacturing and supply chain, and procurement.
From 2011 to 2014, Mr Hodgkinson was Chief Financial Officer and had full financial responsibility for the Novartis ANZ Group of companies and divisions comprising Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, Consumer and Animal Health.
Previously, he held a number of leadership roles with AstraZeneca in the United Kingdom, including Global Licensing Finance Director, before being appointed Chief Financial Officer for AstraZeneca Australia from 2006 to 2011.
After seven years in Mesoblast’s executive team as Chief Financial Officer and Company Secretary, Ms Jenni Pilcher will depart on 31 August to take up a new role with an Australian biotechnology company as Chief Financial Officer.
The Mesoblast Board and management thank Ms Pilcher for her important contribution to the growth of the company and wish her well in her new position.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.